Today’s New York Times carried a front page article about the high cost of the new prostate cancer treatments. This article seems to be the talk of the town and the talk (based on the comments that have been entered on-line) has been anything but positive. Unfortunately, many of the comments have made with the [...]
Yesterday, Amgen announced that it had submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand its license for XGEVA® (denosumab) to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases. If approved, XGEVA would be the first therapy licensed to prevent or [...]
Dear Friends, If you love the work of Malecare Cancer Support, then tell the world! You may or may not realize it, but Malecare has grown to become America's largest men's cancer survivor support and advocacy national nonprofit. Malecare is a 13-year-old all volunteer organization, and our mission is to help men and their families [...]
The Naval Fleet Reserve Association recently provided the following information regarding updates of the Veterans Administration list of vessels exposed to Agent Orange during the Vietnam conflict. This will include many more veterans eligible for VA care for the many diseases attributed to this product. […]
According to findings from a long term study, men with prostate cancer (PCa) who are treated with degarelix (a newly approved gonadotropin-releasing hormone receptor (GnRH) blocker) have a lower risk of PSA failure or death compared with those treated with leuprolide. […]